NATRECOR
LOE ApproachingPeptidenesiritide
NDAINTRAVENOUSFOR SOLUTION
Approved
Aug 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
2/8 — Basic
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NATRECOR (nesiritide) is a recombinant B-type natriuretic peptide administered intravenously for acute decompensated heart failure. It works by binding to natriuretic peptide receptors, promoting vasodilation, natriuresis, and diuresis to reduce cardiac filling pressures. The drug is indicated for patients with acute heart failure presenting with dyspnea at rest or minimal exertion.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), signaling potential team consolidation and shift toward lifecycle management over growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion
Started Oct 2008
0Heart Failure
An Exploratory Study of Nesiritide in Participants With Acute Heart Failure
Started Mar 2007
67 enrolled
Heart Failure, Congestive
An Open-label, One-arm, Study to Evaluate the Hemodynamic Changes and Safety of Nesiritide for Acute Decompensated Heart Failure
Started Oct 2006
41 enrolled
Heart DecompensationCongestive Heart Failure
Nesiritide - Dilated Cardiomyopathy
Started Dec 2003
20 enrolled
Dilated Cardiomyopathy
Career Relevance
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.